167 related articles for article (PubMed ID: 24887335)
61. Analysis of influencing factors on monohydroxylated derivative of oxcarbazepine plasma concentration in children with epilepsy.
Yao N; Huang S; Huang A; Song H
Eur J Clin Pharmacol; 2022 Oct; 78(10):1667-1675. PubMed ID: 36006433
[TBL] [Abstract][Full Text] [Related]
62. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance.
Baruzzi A; Albani F; Riva R
Epilepsia; 1994; 35 Suppl 3():S14-9. PubMed ID: 8156974
[TBL] [Abstract][Full Text] [Related]
63. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians.
Chen CB; Hsiao YH; Wu T; Hsih MS; Tassaneeyakul W; Jorns TP; Sukasem C; Hsu CN; Su SC; Chang WC; Hui RC; Chu CY; Chen YJ; Wu CY; Hsu CK; Chiu TM; Sun PL; Lee HE; Yang CY; Kao PH; Yang CH; Ho HC; Lin JY; Chang YC; Chen MJ; Lu CW; Ng CY; Kuo KL; Lin CY; Yang CS; Chen DP; Chang PY; Wu TL; Lin YJ; Weng YC; Kuo TT; Hung SI; Chung WH;
Neurology; 2017 Jan; 88(1):78-86. PubMed ID: 27913699
[TBL] [Abstract][Full Text] [Related]
64. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
Ahmad A; Garnett WR
Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
[TBL] [Abstract][Full Text] [Related]
65. [Oxcarbazepine].
Arroyo S
Neurologia; 2001 Oct; 16(8):370-5. PubMed ID: 11738014
[TBL] [Abstract][Full Text] [Related]
66. Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication.
Kong ST; Lim SH; Chan E; Ho PC
J Clin Pharmacol; 2014 Feb; 54(2):225-33. PubMed ID: 23996245
[TBL] [Abstract][Full Text] [Related]
67. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication.
Vainionpää LK; Mikkonen K; Rättyä J; Knip M; Pakarinen AJ; Myllylä VV; Isojärvi JI
Epilepsia; 2004 Mar; 45(3):197-203. PubMed ID: 15009219
[TBL] [Abstract][Full Text] [Related]
68. Population pharmacokinetics of carbamazepine in Singapore epileptic patients.
Chan E; Lee HS; Hue SS
Br J Clin Pharmacol; 2001 Jun; 51(6):567-76. PubMed ID: 11422016
[TBL] [Abstract][Full Text] [Related]
69. Oxcarbazepine.
Tecoma ES
Epilepsia; 1999; 40 Suppl 5():S37-46. PubMed ID: 10530693
[TBL] [Abstract][Full Text] [Related]
70. Bioequivalence of oxcarbazepine oral suspension vs. film-coated tablet in healthy Chinese male subjects.
Souppart C; Yin Q; Merz M; Hu P; Jiang J; Appel-Dingemanse S
Int J Clin Pharmacol Ther; 2008 Oct; 46(10):538-44. PubMed ID: 18826868
[TBL] [Abstract][Full Text] [Related]
71. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid.
Tartara A; Galimberti CA; Manni R; Morini R; Limido G; Gatti G; Bartoli A; Strada G; Perucca E
Br J Clin Pharmacol; 1993 Oct; 36(4):366-8. PubMed ID: 12959317
[TBL] [Abstract][Full Text] [Related]
72. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine.
Rosaria Muscatello M; Pacetti M; Cacciola M; La Torre D; Zoccali R; D'Arrigo C; Migliardi G; Spina E
Epilepsia; 2005 May; 46(5):771-4. PubMed ID: 15857446
[TBL] [Abstract][Full Text] [Related]
73. Population pharmacokinetics of carbamazepine in Chinese epilepsy patients.
Jiao Z; Zhong MK; Shi XJ; Hu M; Zhang JH
Ther Drug Monit; 2003 Jun; 25(3):279-86. PubMed ID: 12766553
[TBL] [Abstract][Full Text] [Related]
74. Effects of carbamazepine and oxcarbazepine on the reproductive endocrine function in women with epilepsy.
Löfgren E; Tapanainen JS; Koivunen R; Pakarinen A; Isojärvi JI
Epilepsia; 2006 Sep; 47(9):1441-6. PubMed ID: 16981858
[TBL] [Abstract][Full Text] [Related]
75. The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice.
Johannessen Landmark C; Svendsen T; Dinarevic J; Kufaas RF; Reimers A; Brodtkorb E; Baftiu A; Burns ML; Johannessen SI
Ther Drug Monit; 2016 Aug; 38(4):499-505. PubMed ID: 27414974
[TBL] [Abstract][Full Text] [Related]
76. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers?
Di Girolamo G; Opezzo JA; Schere D; Gonzalez CD; Moncalvo JJ
Expert Opin Pharmacother; 2007 Jul; 8(10):1415-23. PubMed ID: 17661724
[TBL] [Abstract][Full Text] [Related]
77. Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs.
Volosov A; Sintov A; Bialer M
Ther Drug Monit; 1999 Apr; 21(2):219-23. PubMed ID: 10217343
[TBL] [Abstract][Full Text] [Related]
78. Oxcarbazepine in infants and young children with partial seizures.
Northam RS; Hernandez AW; Litzinger MJ; Minecan DN; Glauser TA; Mangat S; Zheng C; Souppart C; Sturm Y
Pediatr Neurol; 2005 Nov; 33(5):337-44. PubMed ID: 16243221
[TBL] [Abstract][Full Text] [Related]
79. Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy.
Ortenzi A; Paggi A; Foschi N; Sabbatini D; Pistoli E
Funct Neurol; 2008; 23(2):97-100. PubMed ID: 18671911
[TBL] [Abstract][Full Text] [Related]
80. Weight gain in children on oxcarbazepine monotherapy.
Garoufi A; Vartzelis G; Tsentidis C; Attilakos A; Koemtzidou E; Kossiva L; Katsarou E; Soldatou A
Epilepsy Res; 2016 May; 122():110-3. PubMed ID: 27010568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
